Olin Shorts Hit One-Year High Ahead of Q3 Print

Olin Corporation reports Q3 results today with short sellers at their most aggressive in at least a year, even as the stock has stabilised near multi-year lows.

Short interest has climbed to 14.7% of the free float, up 46% over the past month and 8% in the past week alone. That is a sustained build, not a spike: looking at the daily history, positions have risen almost continuously since mid-September when the float on loan was closer to 10%. The ORTEX short score has tracked this move, reaching 62.1 this week against readings in the mid-50s a month ago, placing Olin in the 4th percentile of its universe on this metric. Despite the heavy positioning, borrow conditions remain relaxed. The cost to borrow is under 0.5% and availability is running at 285% of current short interest, meaning shares to borrow are plentiful relative to what has already been lent out. Short sellers face no meaningful squeeze pressure from the lending market itself.

The debate is essentially about whether the chlor-alkali cycle is turning. Bulls point to rising caustic soda prices in North America and persistent ammunition demand from Olin's Winchester division, arguing the company has the discipline, via its "value over volume" commercial model, to capture margin as markets tighten. Bears counter that Olin's heavy maintenance and turnaround schedule for 2026 is suppressing near-term profitability, with raw material costs and merchant chlorine competition compounding the pressure. Analyst targets have moved sharply lower ahead of today's print: Truist cut its target to $15 on October 20, and RBC dropped to $16 on October 13, both maintaining cautious ratings. Barclays initiated at Equal-Weight with an $18 target on the same day. UBS and Wells Fargo both trimmed to $18 and $16 respectively earlier in October. The consensus mean now sits at $19.25, well above the current price of $16.05, though the direction of recent revisions is consistently downward. The PE ratio has expanded sharply over the past 30 days to around 58x, reflecting earnings compression rather than re-rating optimism.

The stock has recovered 3.3% over the past week, lagging the median move of 4.7% for its closest chemical peers. HUN gained 10.7% on the week, TROX rose 14.1%, and DOW added 12.3%. Olin's relative underperformance is notable given the broad sector tailwind, and reinforces the scale of the bearish positioning the company is carrying into this release.

ORTEX forecasts a 90% probability that Olin moves from the Russell 1000 to the Russell 2000 at the December 2026 Semi-Annual Review, with the announcement expected on November 13. The implied tracker buying for the Russell 2000 addition stands at roughly $247 million, equivalent to 4.2 days of normal volume. That is a mechanical flow that sits in the background regardless of today's result, though past Russell moves of this type have produced a median price change of negative 4% from announcement to effective date, with only 55% moving in the expected direction.

Today's print tests whether Olin's earnings trajectory can justify a re-rating, or whether the continued margin pressure the Street has been trimming for gives the bears reason to extend a position that has nearly doubled in size since September.